Toxicities of 245 patients with CML in chronic phase, by treatment arm
| . | Imatinib 400 mg/d, N = 123, n (%) . | Dasatinib 100 mg/d, N = 122, n (%) . | ||
|---|---|---|---|---|
| All grades . | Grade 3-4 . | All grades . | Grade 3-4 . | |
| Hematologic toxicities | ||||
| Hemoglobin | 87 (71) | 5 (4) | 87 (71) | 12 (10) |
| Neutrophils | 45 (37) | 15 (12) | 45 (37) | 18 (15) |
| Febrile neutropenia | 0 (0) | 0 (0) | 3 (2) | 3 (2) |
| Platelets | 42 (34) | 10 (8) | 71 (58) | 22 (18) |
| Fluid retention | ||||
| Edema (any) | 61 (50) | 3 (2) | 28 (23) | 1 (1) |
| Pleural effusion | 2 (2) | 1 (1) | 21 (17) | 3 (2) |
| Pericardial effusion | 0 (0) | 0 (0) | 4 (3) | 3 (2) |
| Gastrointestinal toxicities | ||||
| Diarrhea | 51 (41) | 2 (2) | 41 (34) | 6 (5) |
| Nausea | 63 (51) | 1 (1) | 34 (28) | 0 (0) |
| Vomiting | 25 (20) | 0 (0) | 20 (16) | 1 (1) |
| Anorexia | 12 (10) | 0 (0) | 22 (18) | 0 (0) |
| Other nonhematologic toxicities | ||||
| Fatigue | 67 (54) | 1 (1) | 67 (55) | 1 (1) |
| Musculoskeletal pain (any) | 54 (44) | 2 (2) | 39 (32) | 3 (2) |
| Rash | 35 (28) | 2 (2) | 41 (34) | 0 (0) |
| Headache | 23 (19) | 3 (2) | 34 (28) | 3 (2) |
| Prolonged QTc interval | 1 (1) | 0 (0) | 2 (2) | 1 (1) |
| . | Imatinib 400 mg/d, N = 123, n (%) . | Dasatinib 100 mg/d, N = 122, n (%) . | ||
|---|---|---|---|---|
| All grades . | Grade 3-4 . | All grades . | Grade 3-4 . | |
| Hematologic toxicities | ||||
| Hemoglobin | 87 (71) | 5 (4) | 87 (71) | 12 (10) |
| Neutrophils | 45 (37) | 15 (12) | 45 (37) | 18 (15) |
| Febrile neutropenia | 0 (0) | 0 (0) | 3 (2) | 3 (2) |
| Platelets | 42 (34) | 10 (8) | 71 (58) | 22 (18) |
| Fluid retention | ||||
| Edema (any) | 61 (50) | 3 (2) | 28 (23) | 1 (1) |
| Pleural effusion | 2 (2) | 1 (1) | 21 (17) | 3 (2) |
| Pericardial effusion | 0 (0) | 0 (0) | 4 (3) | 3 (2) |
| Gastrointestinal toxicities | ||||
| Diarrhea | 51 (41) | 2 (2) | 41 (34) | 6 (5) |
| Nausea | 63 (51) | 1 (1) | 34 (28) | 0 (0) |
| Vomiting | 25 (20) | 0 (0) | 20 (16) | 1 (1) |
| Anorexia | 12 (10) | 0 (0) | 22 (18) | 0 (0) |
| Other nonhematologic toxicities | ||||
| Fatigue | 67 (54) | 1 (1) | 67 (55) | 1 (1) |
| Musculoskeletal pain (any) | 54 (44) | 2 (2) | 39 (32) | 3 (2) |
| Rash | 35 (28) | 2 (2) | 41 (34) | 0 (0) |
| Headache | 23 (19) | 3 (2) | 34 (28) | 3 (2) |
| Prolonged QTc interval | 1 (1) | 0 (0) | 2 (2) | 1 (1) |
CML indicates chronic myeloid leukemia; and QTc, corrected QT interval.